French specialty-driven biotechnological company Ipsen S.A. (IPSEY) announced Monday that it has appointed David Meek as Chief Executive Officer, effective July 18.
As announced earlier, Marc de Garidel, current Chairman and CEO of Ipsen, will assume the role of non-executive chairman. He will continue to serve the Board of Directors through his deep industry expertise. In addition, Garidel will advise Mayroy, the Ipsen controlling holding company.
In mid February, Ipsen had said that its board has decided to adapt its corporate governance by separating the functions of Chairman and Chief Executive Officer, under the conditions laid down in the company's bylaws and after consulting the Nominations & Governance Committee.
Meek will be based at Ipsen's headquarters in Boulogne-Billancourt. His mission is to ensure the continued growth and innovative pipeline development of the specialty and primary care businesses, and to advance the international expansion especially in the United States and China.
Meek, an American national, has over 25 years of experience in the pharmaceutical industry. Most recently, he was Executive Vice-President and President of the oncology division of Baxalta Inc., which was recently acquired by Shire.
He was with Novartis from 2005 to 2012, where he successively served as the global business franchise head for respiratory and dermatology franchise, President and Chief Executive Officer of the pharmaceutical division in Canada, and the head of oncology for Northern, Central and Eastern Europe, based in Milan, Italy.
From 2012 to 2014, he served as Chief Commercial Officer of Endocyte, an American biotechnology company.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.